Diasome to Present at the Solebury Trout Summer 2020 Private Company Showcase
August 04, 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome to Present at the LifeSci Partners Summer Symposium
July 28, 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, July 28, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
June 15, 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, June 15, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome to Present Data from Phase 2 OPTI-1 Clinical Trial at the 80th Annual American Diabetes Association Virtual Scientific Sessions
June 04, 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, June 04, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
February 18, 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference
February 12, 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., today announced an upcoming ePoster presentation highlighting additional results from the Phase 2b InSulin Liver Effect-1...
Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board
December 10, 2019 10:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals today named Dr. Jeremy Pettus the chairman of the company’s scientific advisory board. Dr. Pettus is a board-certified...
Diasome Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference
November 26, 2019 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any insulin to improve blood...
Diasome Announces Publication of Phase 2b Results in Diabetes Care
September 24, 2019 10:51 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals today announced the online publication of its InSulin Liver Effect (ISLE-1) Phase 2b study results in respected...
Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
June 25, 2019 10:04 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, June 25, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any insulin to improve blood...